PRME
Prime Medicine Inc.
$3.16
+$0.29(+10.10%)
45
Overall
55
Value
40
Tech
42
Quality
Market Cap
$731.07M
Volume
4.21M
52W Range
$1.18 - $6.94
Target Price
$6.92
Order:
Income Statement
| Metric | Trend | Chart | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|
| REVENUE | ||||||
| Total Revenue | $294.0K | $168.0K | $3.0M | $4.6M | ||
| Total Revenue | $294.0K | $168.0K | $3.0M | $4.6M | ||
| GROSS PROFIT | ||||||
| Gross Profit | $294.0K | $168.0K | $3.0M | $4.6M | ||
| OPERATING EXPENSES | ||||||
| Operating Expenses | $116.5M | $204.8M | $205.4M | $213.0M | ||
| Research & Development | $86.7M | $147.9M | $155.3M | $160.6M | ||
| Research Expense | $86.7M | $147.9M | $155.3M | $160.6M | ||
| Selling, General & Administrative | $29.8M | $43.4M | $50.2M | $52.3M | ||
| General & Administrative Expenses | $29.8M | $43.4M | $50.2M | $52.3M | ||
| Depreciation & Amortization | $2.2M | $4.7M | $6.1M | -- | ||
| Depreciation & Amortization | $2.2M | -- | -- | -- | ||
| Other Operating Expenses | $13.2M | $204.8M | $205.4M | $213.0M | ||
| OPERATING INCOME | ||||||
| Operating income | $-116.5M | $-204.8M | $-202.5M | $-208.3M | ||
| EBITDA | $-114.3M | $-184.4M | $-177.4M | $-184.1M | ||
| NON-OPERATING ITEMS | ||||||
| Intinc | -- | $2.8M | $3.5M | $6.6M | ||
| Net Non-Operating Interest Income/Expense | -- | $2.8M | $3.5M | $6.6M | ||
| Other Income/Expense | $-6.2M | $-274.0K | $-3.5M | $-148.0K | ||
| Other Special Charges | $-6.2M | $274.0K | $41.0K | $148.0K | ||
| SPECIAL ITEMS | ||||||
| Special Income Charges | -- | $5.7M | -- | -- | ||
| PRE-TAX INCOME | ||||||
| EBIT | $-116.5M | $-198.4M | $-195.9M | $-201.1M | ||
| Pre-Tax Income | $-122.8M | $-182.5M | $-195.4M | $-201.6M | ||
| INCOME TAX | ||||||
| Tax Provision | $-948.0K | $-279.0K | -- | -- | ||
| NET INCOME | ||||||
| Net Income | $-121.8M | $-198.1M | $-195.9M | $-201.1M | ||
| Net Income (Continuing Operations) | $-121.8M | $-198.1M | $-195.9M | $-201.1M | ||
| Net Income (Discontinued Operations) | $-121.8M | $-198.1M | $-195.9M | $-201.1M | ||
| Net Income (Common Stockholders) | $-142.0M | $-198.1M | $-195.9M | $-201.1M | ||
| Normalized Income | -- | -- | -- | $-199.6M | ||
| TOTALS | ||||||
| Total Expenses | $116.5M | $204.8M | $205.4M | $213.0M | ||
| SHARE & EPS DATA | ||||||
| Average Shares Outstanding | $33.9M | $91.0M | $118.6M | $148.8M | ||
| Average Shares Outstanding (Diluted) | $33.9M | $91.0M | $118.6M | $148.8M | ||
| Shares Outstanding | $97.2M | $119.9M | $131.2M | $180.6M | ||
| Basic EPS | $-4.19 | $-2.18 | $-1.65 | $-1.35 | ||
| Basic EPS (Continuing Operations) | $-4.19 | $-2.18 | $-1.65 | $-1.35 | ||
| Diluted EPS | $-4.19 | $-2.18 | $-1.65 | $-1.35 | ||
| Diluted EPS (Continuing Operations) | $-4.19 | $-2.18 | $-1.65 | $-1.35 | ||
| OTHER METRICS | ||||||
| Accrued Preferred Stock Dividends | $162.2M | $198.1M | -- | -- | ||
| Acquired In Process Rn D | -- | $5.7M | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | $3.5M | -- | ||
| Other Gand A | $29.8M | $43.4M | $50.2M | $52.3M | ||
| Preferred Stock Dividends | $162.2M | $198.1M | -- | -- | ||
| Realized Capital Gain | -- | -- | $3.5M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PRME | $3.16 | +10.1% | 4.21M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |